logo
Plus   Neg
Share
Email

DCC Plc FY Adj. Operating Profit Rises; Revenue Down 3.1% - Quick Facts

DCC Plc (DCC.L) reported pretax profit of 311.5 million pounds for the year ended 31 March 2020 compared to 327.4 million pounds, prior year. Earnings per share was 249.21 pence compared to 279.73 pence. Adjusted operating profit rose 7.3 percent, or 7.6 percent on a constant currency basis, to 494.3 million pounds. Adjusted earnings per share increased to 362.02 pence from 357.63 pence.

Fiscal year revenue declined to 14.8 billion pounds from 15.2 billion pounds, previous year. Group revenue decreased by 3.1% primarily driven by the lower oil price that prevailed during the year.

The Board proposed a 2.6% increase in the final dividend to 95.79 pence per share, which, when added to the interim dividend of 49.48 pence per share, gives a total dividend for the year of 145.27 pence per share. This represents a 5.0% increase over prior year dividend. It is proposed to pay the final dividend on 23 July 2020 to shareholders on the register at the close of business on 29 May 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
RELATED NEWS
Follow RTT